Literature DB >> 16757267

The marginal donor: a single-center experience in orthotopic liver transplantation.

V Scuderi1, A Ceriello, P Maida, G Aragiusto, G Arenga, T Carfora, M Defez, A Giuliani, G N Monti, W Santaniello, F Sicoli, F Calise.   

Abstract

The use of marginal donors has become more common worldwide due to the sharp increase in recipients with a consequent shortage of suitable organs. The definition of "marginal donor" has not been reached by all centers. We herein analyzed our single-center experience over the last 3 years in liver transplantation (OLT) to evaluate the outcomes of using a high percentage of so-called "marginal donors", according to the current classification from the National (Italian) Center of Transplantation (CNT). Among the 78 OLT performed in 77 patients from January 1, 2003 to October 31, 2005, donor livers were divided into three groups according to the CNT classification. We evaluated donor variables, cold ischemia time (CIT), warm ischemia time (WIT), MELD score, and length of hospital stay. Histologic graft steatosis was correlated with estimated steatosis by ultrasound. There were no differences among the three graft recipient groups concerning CIT, WIT, MELD score, and the length of hospital stay. Steatosis is indicated in all series as a definite variable for a higher risk of postoperative mortality. CIT is necessarily related to donor retrieval policy and organization. Donor age seemed also to be related to a possible increase in postoperative mortality, but there are significant variations in the definition of the age limit. We failed to observe a correlation between a higher mortality rate and any of the variables currently listed to define a "marginal donor." A shorter CIT seemed to positively influence the role played by the other variables identifying a "marginal liver." Finally, the use of HCV(+) or HBV(+) grafts did not lead to an increased mortality.

Entities:  

Mesh:

Year:  2006        PMID: 16757267     DOI: 10.1016/j.transproceed.2006.04.003

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  6 in total

1.  Cyclopamine attenuates acute warm ischemia reperfusion injury in cholestatic rat liver: hope for marginal livers.

Authors:  Akshay Pratap; Ravikiran Panakanti; Ningning Yang; Ramasubramanian Lakshmi; Kian A Modanlou; James D Eason; Ram I Mahato
Journal:  Mol Pharm       Date:  2011-05-06       Impact factor: 4.939

2.  Recent advances and controversies in surgical management of liver diseases: summary of liver sessions of 7th World Congress of IHPBA 2006.

Authors:  Ronnie T P Poon
Journal:  HPB (Oxford)       Date:  2007       Impact factor: 3.647

3.  Preservation of non-heart-beating donor livers in extracorporeal liver perfusion and histidine-trytophan-ketoglutarate solution.

Authors:  Jin Gong; Xue-Jun Lao; Xi-Mo Wang; Gang Long; Tao Jiang; Shi Chen
Journal:  World J Gastroenterol       Date:  2008-04-21       Impact factor: 5.742

4.  Transplantation of Deceased Donor Livers With Elevated Levels of Serum Transaminases at Shiraz Transplant Center.

Authors:  Nasir Fakhar; Saman Nikeghbalian; Kourosh Kazemi; Ali Reza Shamsayeefar; Siavash Gholami; Amir Kasraianfard; Seyed Ali Malek-Hosseini
Journal:  Hepat Mon       Date:  2016-10-08       Impact factor: 0.660

5.  Biliverdin protects against liver ischemia reperfusion injury in swine.

Authors:  Barbara Andria; Adele Bracco; Chiara Attanasio; Sigismondo Castaldo; Maria Grazia Cerrito; Santolo Cozzolino; Daniele Di Napoli; Roberto Giovannoni; Antonio Mancini; Antonino Musumeci; Ernesto Mezza; Mario Nasti; Vincenzo Scuderi; Stefania Staibano; Marialuisa Lavitrano; Leo E Otterbein; Fulvio Calise
Journal:  PLoS One       Date:  2013-07-29       Impact factor: 3.240

6.  A novel technique for central hepatectomy: Maintain the blood supply and biliary drainage on one side and the blood supply from the portal vein on the other.

Authors:  Chun Tang; Jun-Tao Yang; Hong-Xu Chen; Xian-Chun Liang; Hong-Ming Liu; Ping Chen
Journal:  Exp Ther Med       Date:  2013-10-29       Impact factor: 2.447

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.